In the course of the development of TF-targeted therapeutics, Hu and Garen have previously developed fVII(K341A)/IgG1 Fc (Icon) immunoconjugates for immunotherapy of cancer [2-5], wMD [7,8], and endometriosis[9]. This evidence concerns the gene TF and cancer.